{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T05:20:21Z","timestamp":1788931221955,"version":"build-2803163510"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Isolated adrenocorticotropic hormone (ACTH) deficiency (IAD) is an uncommon endocrine disorder characterised by the selective reduction or absence of pituitary ACTH secretion, resulting in secondary adrenal insufficiency while other pituitary hormone axes remain functional. The clinical manifestations of this condition are frequently non-specific, and may include symptoms such as fatigue, decreased appetite, weight loss, hypotension, and hyponatremia. These symptoms can be easily confused with those of other diseases, resulting in either missed diagnoses or misdiagnoses. Glucocorticoid replacement therapy is generally considered to provide effective symptom relief and a favourable prognosis. In recent years, the widespread use of immune checkpoint inhibitors (ICIs) in cancer treatment has resulted in a significant increase in immune-related adverse events (irAEs). Isolated ACTH deficiency has been reported as a rare yet severe endocrine-type irAE, potentially arising from immune-mediated pituitary injury. In view of the nonspecific nature of its clinical presentation, early recognition and timely intervention are of critical importance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>The present study reports the case of a patient diagnosed with gastric adenocarcinoma who underwent laparoscopic total gastrectomy, followed by combination therapy with oxaliplatin (OXA), nivolumab, and trastuzumab. Approximately eight months into the treatment regimen, the patient exhibited symptoms of isolated ACTH deficiency and hypothyroidism, indicative of a multi-endocrine system adverse reaction. Such multi-system endocrine dysfunction following this combination therapy is relatively uncommon. The present study analyses the patient\u2019s clinical presentation, laboratory findings, and imaging data, and discusses the differential diagnosis from post-gastrectomy dumping syndrome.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case demonstrates that in patients with malignant tumours receiving nivolumab and trastuzumab therapy, the presence of unexplained hypoglycaemia, persistent fatigue, anorexia, nausea, or vomiting \u2013 non-specific symptoms \u2013 should raise high suspicion for immune-related endocrine adverse reactions. It is imperative to emphasise the significance of preliminary testing for serum cortisol, ACTH, and thyroid function levels. Early recognition and prompt initiation of hormone replacement therapy can effectively prevent misdiagnosis, missed diagnosis, and delayed treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1742701","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:14:03Z","timestamp":1776658443000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case report and literature review: isolated ACTH deficiency induced by combined nivolumab and trastuzumab therapy in gastric adenocarcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Liwei","family":"Shi","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Graduate School of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Department of Endocrinology, Harrison International Peace Hospital","place":["Hengshui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinrong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Critical Care Medicine, Harrison International Peace Hospital","place":["Hengshui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Xie","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Graduate School of Hebei Medical University","place":["Shijiazhuang, China"]},{"name":"Department of Endocrinology, Harrison International Peace Hospital","place":["Hengshui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Harrison International Peace Hospital","place":["Hengshui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.918427","article-title":"Isolated adrenocorticotropic hormone deficiency presenting with severe hyponatremia and rhabdomyolysis: a case report and literature review","volume":"20","author":"Komatsu","year":"2019","journal-title":"Am J Case Rep"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1210\/jcem-14-12-1519","article-title":"True pituitary Addison's disease, a pituitary unitropic deficiency; fifteen-year follow-up","volume":"14","author":"Steinberg","year":"1954","journal-title":"J Clin Endocrinol Metab"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2017.06.007","article-title":"Nivolumab and pembrolizumab: monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable","volume":"44","author":"Prasad","year":"2017","journal-title":"Semin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4591","article-title":"Combination cancer immunotherapy and new immunomodulatory targets","volume":"14","author":"Mahoney","year":"2015","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.3410","article-title":"Study and analysis of antitumor resistance mechanism of PD1\/PD-L1 immune checkpoint blocker","volume":"9","author":"Wang","year":"2020","journal-title":"Cancer Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1084\/jem.20160801","article-title":"PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity","volume":"214","author":"Juneja","year":"2017","journal-title":"J Exp Med"},{"key":"B7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ctrv.2016.02.003","article-title":"Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy","volume":"45","author":"Eigentler","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1200\/JCO.2010.29.5865","article-title":"Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy","volume":"29","author":"Burris","year":"2011","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119674","article-title":"Mechanisms of resistance to antibody-drug conjugates","volume":"24","author":"Khoury","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1167975","article-title":"Immune-related adverse events of immune checkpoint inhibitors: a review","volume":"14","author":"Yin","year":"2023","journal-title":"Front Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.coi.2021.02.002","article-title":"Adverse events induced by immune checkpoint inhibitors","volume":"69","author":"Perdigoto","year":"2021","journal-title":"Curr Opin Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.722586","article-title":"Case report: a variety of immune-related adverse events triggered by immune checkpoint inhibitors in a subject with Malignant melanoma: destructive thyroiditis, aseptic meningitis and isolated ACTH deficiency","volume":"12","author":"Katakura","year":"2021","journal-title":"Front Endocrinol Lausanne"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1177\/1060028021998320","article-title":"A review of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer","volume":"55","author":"Nguyen","year":"2021","journal-title":"Ann Pharmacother"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/sajc.sajc_400_18","article-title":"Severe hypoglycemia with trastuzumab: an unseen adverse event","volume":"8","author":"Amrith","year":"2019","journal-title":"South Asian J Cancer"},{"key":"B16","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1111\/obr.12467","article-title":"Dumping syndrome after esophageal, gastric or bariatric surgery: pathophysiology, diagnosis, and management","volume":"18","author":"van Beek","year":"2017","journal-title":"Obes Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-020-0357-5","article-title":"International consensus on the diagnosis and management of dumping syndrome","volume":"16","author":"Scarpellini","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-002-0061-7","article-title":"Dumping syndrome","volume":"5","author":"Hasler","year":"2002","journal-title":"Curr Treat Opt Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2017.04.028","article-title":"The short- to mid-term symptom prevalence of dumping syndrome after primary gastric-bypass surgery and its impact on health-related quality of life","volume":"13","author":"Emous","year":"2017","journal-title":"Surg Obes Relat Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2014.07.010","article-title":"Complications of bariatric surgery: dumping syndrome, reflux and vitamin deficiencies","volume":"28","author":"Tack","year":"2014","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13256-018-1800-2","article-title":"Transient severe distributive shock due to early dumping syndrome: a case report","volume":"12","author":"Takeshita","year":"2018","journal-title":"J Med Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.ej12-0288","article-title":"Octreotide improves early dumping syndrome potentially through incretins: a case report","volume":"60","author":"Sato","year":"2013","journal-title":"Endocr J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000002651","article-title":"Frequency of abnormal glucose tolerance test suggestive of dumping syndrome following oesophageal atresia repair","volume":"70","author":"Aumar","year":"2020","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1742701\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T04:14:04Z","timestamp":1776658444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1742701\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":23,"alternative-id":["10.3389\/fendo.2026.1742701"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1742701","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"article-number":"1742701"}}